جست‌وجوی استاد و پژوهشگر

Derek Allisonمشاهده پروفایل

دانشیار

• Cytopathology
• Molecular surgical pathology
• Cancer metabolism
• +۷ مورد دیگر

Derek Allison, MD, is Associate Professor of Pathology and Laboratory Medicine at the University of Kentucky College of Medicine, Vice-Chair for Research, Assistant Director of the Biospecimen Procurement & Translational Pathology Shared Resource, and Director of the Molecular Tumor Board at the Markey Cancer Center. His federally funded translational program bridges high-volume cytopathology service with multi-omic cancer metabolism, glycomics, and AI-driven predictive biomarkers. Education & Training: BS Biochemistry, Lipscomb University (2010) MD, Georgetown University (2014) AP/CP Residency, Johns Hopkins University School of Medicine (2018) Cytopathology Fellowship, Johns Hopkins University School of Medicine (2019) Research Focus: Dr. Allison’s group uses spatial mass-spectrometry imaging, single-cell sequencing, and machine learning to decode metabolic heterogeneity in lung and prostate cancers. Major themes include glycogen and N-glycan drivers of tumor initiation, PLK1-mediated therapy resistance, and AI-powered pathology assays that predict response to intravesical BCG in high-risk bladder cancer. Recent Publication Trends: From 2021-2025 he has >60 peer-reviewed articles centered on three intersecting tracks: (1) glycomics/glycogen biology in lung adenocarcinoma and pulmonary fibrosis, (2) PLK1 and kinase signaling in prostate and lung cancers, and (3) real-world validation of AI biomarkers in urothelial malignancies. His work consistently appears in high-impact journals such as Nature Metabolism , Nature Communications , Cell Reports Medicine , and Cancer Cytopathology . Leadership & Service: He directs the Molecular Tumor Board at Markey Cancer Center, leads the BPTP biobank, and serves on multiple NCI-funded consortia for precision oncology. He mentors pathology residents, graduate students, and clinical fellows in projects spanning interventional cytopathology to computational metabolomics.

• Urological Neoplastic Pathology
• Sarcomas
• Prostate Cancer Diagnosis and Treatment
• +۷ مورد دیگر

Piergiuseppe Colombo is an Associate Professor of Pathological Anatomy at Humanitas University (Milan, Italy), specializing in urological oncopathology and sarcomas. He holds roles in academic training, including Adjunct Teaching Professor roles in specialized programs. His research focuses on diagnostic advancements in prostate and bladder cancers, molecular pathology, and imaging techniques like PSMA PET/CT and HIFU. Education: Graduated in Medicine from the University of Milan (1995), specialized in Pathological Anatomy (1999). He has held leadership roles, including Head of Surgical Diagnostics in Pathological Anatomy (2009), and sits on national panels for histological review of prostatic biopsies (PRIAS) and the Genitourinary Pathology Society (GUPS). Research Interests: Urological cancers (prostate/bladder), sarcomas, molecular diagnostics, tumor immune microenvironment, imaging innovations (PSMA PET/CT, micro-ultrasound), and clinical trials for focal therapies. Publications highlight studies on tumor biology, diagnostic accuracy, and clinical outcomes in cancer management. His work bridges laboratory research (e.g., immune profiling) with clinical applications (e.g., HIFU focal therapy for prostate cancer). Teaching: Lectured in oncological pharmacology, urology, and pathological anatomy at Humanitas University and the University of Milan. Active in mentoring through specialization programs.

• Oncology
• Virology
• Immunotherapy
• +۴ مورد دیگر

Dr Guy Simpson is a Research Fellow in Oncology at the University of Surrey's School of Biosciences. He holds a PhD in 'Optimising therapeutic herpes simplex vectors for cancer' from UCL (2004), an MPhil in Human Endogenous Retroviral research (1997), and a BSc in Bioanalytical Science (1988). His career includes roles as Senior Scientist at UCL/BioVex Ltd (2004–2007) and Research Associate at the University of Liverpool (1995–1999). Research Interests: Dr Simpson specializes in oncolytic virotherapy, particularly using Coxsackievirus A21 and herpes simplex viruses, targeting bladder, prostate, and pancreatic cancers. His work focuses on viral-mediated immunotherapy, HOX/PBX gene dysregulation, and tumor microenvironment modification. Key projects include the CANON study evaluating CVA21 for non-muscle-invasive bladder cancer and investigations into EN2 protein biomarkers. Publications: His recent work highlights synergistic effects of oncolytic viruses with chemotherapy, immunotherapy resistance mechanisms, and biomarker discovery. Notable studies include the 2023 analysis of ICAM-1 and CVA21 on bladder carcinoma cell lines and a 2024 paper on p53-driven adenoviral immunotherapy for pancreatic cancer. Labs & Collaborations: Active in interdisciplinary teams exploring viral vectors, immune modulation, and precision oncology. Collaborates with Prof Hardev Pandha and Prof Nicola Annels on translational cancer research projects.

• Cancer Surgery
• Colorectal Surgery
• Oncology
• +۸ مورد دیگر

Arne Wibe is a Clinical Professor affiliated with the Norwegian University of Science and Technology (NTNU), specializing in gastroenterological surgery and oncology. He is part of the Gastroenterology and Inflammation Specialist group, focusing on colorectal surgery, cancer treatment, and translational medicine. His research spans surgical techniques, patient outcomes, and global health challenges, with a particular interest in rectal cancer, anastomotic leakage prevention, and postoperative care. His research interests include colorectal cancer surgery, molecular medicine, and the long-term effects of bariatric procedures. He has contributed to studies on minimally invasive techniques like TAMIS and en bloc radical cystectomy. His work also addresses global surgical access, as seen in studies on healthcare in Sierra Leone. Recent publications highlight advancements in surgical methodologies, patient-reported outcomes, and translational research. His articles often focus on optimizing surgical approaches and improving quality of life post-treatment. Collaborations with international teams underscore his global impact in surgical oncology and healthcare equity.

Carissa Chuمشاهده پروفایل

استادیار

• Urologic Oncology
• Bladder Cancer
• Prostate Cancer
• +۷ مورد دیگر

Dr. Carissa Chu is a physician-scientist and urologic oncologist at the University of California San Francisco (UCSF), affiliated with the Department of Urology in the School of Medicine. Her research is focused on translational studies of bladder and prostate cancers, with an emphasis on understanding drug resistance mechanisms, tumor heterogeneity, and identifying biomarkers to personalize cancer care. Research Interests: Dr. Chu’s work spans urologic oncology, precision medicine, and cancer disparities. She investigates molecular subtypes in urothelial and prostate cancers, the role of targets like NECTIN-4 and TROP2 in therapy response, and the use of imaging and genomic tools in active surveillance. Her research aims to bridge laboratory findings with clinical applications to improve patient outcomes. The recent publications highlight a strong trend toward precision oncology, with a focus on genomic heterogeneity, biomarker development, and optimizing surveillance strategies in prostate and bladder cancers. Her work frequently appears in high-impact journals such as Clinical Cancer Research and European Urology . Scientific Awards: Best Poster in Session, Western Section AUA Annual Meeting (2019) NIH TL-1 Translational Research Grant (2020) NIH T-32 Ruth L. Kirschstein National Research Service Award (2022) American Society of Clinical Oncology Young Investigator Award (2022) Ferdinand C. Valentine Award for Research in Urology (2023) NIH K-12 HDFCCC K12 Physician Scientist Program in Clinical Oncology Advising and Grants: While specific students are not listed, Dr. Chu leads a translational research lab and has secured multiple competitive grants, including NIH K12, T32, and TL1 awards, indicating active mentorship and research funding. Her work is supported by major institutions like the NIH and the UCSF CTSI, reflecting her role as an independent investigator in clinical oncology research. Labs and Teams: Dr. Chu runs a translational research laboratory focused on tumor tissue analysis in urologic cancers. She collaborates extensively with multidisciplinary teams at UCSF and Memorial Sloan Kettering, contributing to large-scale studies on cancer disparities, imaging, and therapeutic resistance.

Arno van Leendersمشاهده پروفایل

استاد

• Prostate Cancer
• Bladder Cancer
• Neoplasm
• +۵ مورد دیگر

Arno van Leenders is a full professor at Erasmus MC specializing in Pathology with a focus on Prostate Cancer (100% fingerprint) and Bladder Cancer (100% in recent outputs). Active in Neoplasm research (46% fingerprint) and Biopsy Technique development (29%), he collaborates internationally on Prostatectomy (43%) and Gleason Score accuracy (24%). His recent work includes: Multidisciplinary approaches to prostate cancer overdiagnosis Bladder cancer chemotherapy outcomes analysis ARID1A loss modeling in tumoroids 4D pathology for prostate cancer dynamics Research spans Magnetic Resonance Imaging (22%), Neoadjuvant Chemotherapy (100%), and Surgical Margin analysis (18%).

Ali Aminمشاهده پروفایل

استاد

• Genitourinary Pathology
• Prostate Cancer
• Bladder Cancer
• +۴ مورد دیگر

Ali Amin, MD, is Professor of Surgery and Professor of Pathology and Laboratory Medicine at the Warren Alpert Medical School of Brown University, and Director of Genitourinary Pathology services at The Miriam Hospital. A board-certified anatomic and clinical pathologist, he completed medical school and pathology residency at Shiraz University of Medical Sciences, followed by residencies at St. Luke’s-Roosevelt Hospital Center (where he served as chief resident) and fellowships in oncology/surgical pathology at Memorial Sloan Kettering Cancer Center and GU pathology at Johns Hopkins Hospital. Education 1997 – MD, Shiraz University of Medical Sciences, Shiraz, Iran Anatomic & Clinical Pathology Residency, St. Luke’s-Roosevelt Hospital Center, New York, NY Fellowship – Surgical/Oncological Pathology, Memorial Sloan Kettering Cancer Center Fellowship – Genitourinary Pathology, Johns Hopkins Hospital Research Focus Dr. Amin’s research is centered on clinical and translational pathology of genitourinary tumors, with an emphasis on improving diagnosis, prognostication, and management of prostate, bladder, and renal neoplasms. He actively investigates diagnostic biomarkers, molecular subtypes of urothelial carcinoma, and quality assurance strategies for pathology reporting. His work integrates advanced immunohistochemistry, digital pathology, and deep-learning approaches to refine cancer grading and treatment planning. Publication Trends Across more than 55 peer-reviewed articles published since 2003, Dr. Amin’s scholarly output spans high-impact journals such as European Urology , PNAS , Human Pathology , and Urologic Oncology . Recurring themes include (1) Gleason grading and histopathologic variants of prostate cancer, (2) molecular characterization and prognostication of urothelial carcinoma, (3) novel imaging probes for intraoperative margin assessment, and (4) quality assurance and standardization in pathology reporting. His collaborative studies incorporate multi-institutional cohorts, experimental animal models, and cutting-edge AI algorithms. Teaching & Mentorship Awards Outstanding Mentor Certificate of Appreciation – Brown University, 2018 Alan Podis Teaching Award – Brown Urology Department, 2013–2014 Ronald DeLellis Mentoring Award – Brown Pathology Department, 2013–2014 Best Teacher in Anatomical Pathology – Brown University, 2011–2013 Best Resident Research Publication – Shiraz University, 2004 Leadership & Service Dr. Amin directs the Surgical Pathology Fellowship and serves as residency site director at The Miriam Hospital. He has held leadership roles within the Rhode Island Society of Pathologists and the United States and Canadian Academy of Pathology, and maintains active membership in the Genitourinary Pathology Society, American Urological Association, USCAP, CAP, ASCP, and ISUP.

Yuanpu Peter Diمشاهده پروفایل

استاد

• Environmental Health
• Pulmonary Immunology
• Antimicrobial Resistance
• +۳ مورد دیگر

Yuanpu Peter Di is a Professor at the University of Pittsburgh in the Department of Environmental and Occupational Health. His research explores environmental exposure impacts on pulmonary host defense, chronic disease pathogenesis, and antimicrobial resistance (AMR) mechanisms. Research Interests : Elucidating SPLUNC1/BPIFA1's role in lung immunity and disease Investigating inflammation-associated lung tumorigenesis and K-ras mutation dynamics Developing novel antimicrobial peptides (e.g., PAX, WLBU2) to combat multidrug-resistant infections Studying lung stem cell biology and epithelial repair mechanisms Publications demonstrate expertise in: Environmental toxicant effects on respiratory systems Antimicrobial peptide-membrane interactions Host-pathogen dynamics in bacterial/viral coinfections Translational applications of urinary bladder matrix Genomic approaches to lung disease mechanisms His work combines in vitro and in vivo models with advanced bioinformatics and molecular biology techniques.

• Cell Biology
• Cancer Research
• DNA Replication
• +۴ مورد دیگر

Bart Westendorp is an Associate Professor and Department Chair (2023-2027) at Utrecht University's Faculty of Veterinary Medicine, Department of Biomolecular Health Sciences. His primary affiliation is with the Cell Biology, Metabolism & Cancer research group, and he maintains a dual appointment at the Hubrecht Institute (Uppsalalaan 8, Room 5.15). His work focuses on understanding cancer therapy resistance mechanisms at the single-cell level. His research expertise centers on cancer cell heterogeneity, DNA replication dynamics, and therapy resistance mechanisms. Using advanced methodologies including single-cell sequencing, live-cell imaging, and flow cytometry, his lab investigates how cancer cells adapt to treatments, particularly in muscle-invasive bladder cancer. Key research themes include E2F transcription factors, cell cycle regulation, replication stress tolerance, and carcinogenesis pathways. Analysis of his recent publications reveals strong trends in single-cell analysis of therapy resistance, with emphasis on FOXM1-mediated replication stress responses, cell cycle braking mechanisms, and kinase remodeling in disease contexts. His work bridges fundamental cell biology with translational cancer research, frequently employing multi-omics approaches to uncover heterogeneity in tumor responses. Professional activities include frequent invited talks on replication stress modeling (2023-2024) and single-cell analysis of bladder cancer drug resistance (2022). His media engagement includes significant coverage of his 2020 research on unstoppable cell cycles in cancer therapy resistance, widely disseminated through academic platforms and social media. His academic journey spans from Biomedical Sciences training at Utrecht University (1996-2001), PhD in Clinical Pharmacology at Groningen (2001-2005), postdoctoral work at Ottawa Heart Institute (2005-2008), to progressive roles at Utrecht University: Postdoctoral Researcher (2008-2012), Researcher (2014-2016), and University Lecturer/Assistant Professor (2016-present), culminating in his current Associate Professorship and Department Chair position.

• Urology
• Andrology
• Robotic Surgery
• +۸ مورد دیگر

Giorgio Franco is a Full Professor of Urology at Sapienza University of Rome, where he serves as Director of the Urology Department at Policlinico Umberto I hospital. He has held academic positions since 1988, progressing from Researcher to Associate Professor (2001-2021) and Full Professor (since 2021). His career spans clinical practice, research, and teaching across urology, with special expertise in robotic surgery, male infertility, andrology, and urological oncology. His research interests encompass robotic and laparoscopic urological surgery, male infertility treatments including micro-TESE procedures, penile prosthetics, prostate and bladder cancer diagnostics and management, and testicular tumor conservation techniques. He has pioneered techniques in testis-sparing surgery for small testicular masses and developed innovative approaches in penile curvature correction and urethral reconstruction. With over 142 indexed publications in Scopus, accumulating more than 2,942 citations and an h-index of 30, his recent work focuses on robotic partial nephrectomy techniques, contrast-enhanced ultrasound applications in bladder cancer detection, penile prosthesis outcomes, and diagnostic approaches for prostate cancer. His research demonstrates consistent innovation in minimally invasive techniques and evidence-based urological practice. Riconoscimento della Jordanian Society for Fertility and genetics (multiple years) Ambasciatore dell'Andrologia (2018) Miglior poster at EAU 2018 Copenhagen Premio 'Top-Andrology' (1999) President of the Italian Society of Andrology (2013-2016) As an educator, Professor Franco has coordinated integrated pathology courses, directed master's programs in robotic urological surgery, and supervised countless medical students and residents. His surgical expertise is evidenced by over 1,600 procedures as lead surgeon in the last five years, including complex robotic prostatectomies, nephrectomies, and penile prosthetic implants. He has organized more than 25 national and international congresses and courses throughout his career, significantly contributing to urological education and knowledge dissemination.

• Pharmacology
• Toxicology
• Pharmaceutical Science
• +۵ مورد دیگر

Farhan Haq is an Associate Researcher at the Division of Medical Microbiology within the Faculty of Medicine at Lund University. His research focuses on molecular mechanisms in infectious diseases and cancer, with particular expertise in bladder cancer, immune responses, and molecular signaling pathways. Dr. Haq's research interests span multiple disciplines including pharmacology, toxicology, molecular biology, and immunology. His work primarily investigates the role of oleic acid derivatives in cancer treatment, immune response mechanisms, and molecular pathways involving FGF21 and mTOR. His research integrates computational modeling with experimental approaches to understand disease mechanisms at the molecular level. Analysis of Dr. Haq's recent publications reveals a strong focus on bladder cancer therapeutics, particularly examining alpha1-oleate treatments and their immune-modulating effects. His research shows consistent integration of molecular biology techniques with clinical applications, demonstrating expertise in both basic science and translational medicine. The publications indicate collaborative work with multiple international researchers, particularly with Svanborg C. and Ambite I., suggesting active participation in research networks. Dr. Haq's work has garnered attention in scientific circles with multiple publications receiving news mentions and social media engagement, including coverage by news outlets and discussions on platforms like X and Reddit. His research on bladder cancer treatments has been particularly visible, with one article referenced by multiple news outlets and discussed across various social media platforms.

• Register-based epidemiology
• Cancer epidemiology
• Obesity and cancer risk
• +۳ مورد دیگر

Christel Häggström is a researcher in register-based epidemiology at Lund University, Sweden. She contributes to large-scale population studies linking obesity, metabolic factors and genetic markers to cancer risk and outcomes, with a focus on bladder and prostate malignancies. Her work supports the UN Sustainable Development Goals by generating evidence that can guide preventive strategies and optimise cancer care. Research interests Häggström’s primary research lies at the intersection of epidemiology, oncology and health economics . Key areas include: Quantifying body-mass-index and metabolic syndrome impacts on over 100 cancer subtypes using Swedish national registries. Evaluating cost-effectiveness of molecularly-guided neoadjuvant chemotherapy in muscle-invasive bladder cancer. Investigating germline PSA polymorphisms and their influence on tumour biology and clinical prognosis in prostate cancer. Methodologically she employs prospective pooled cohort designs, mediation analyses and register linkage, ensuring high external validity and policy relevance. Scientific output trends Across her 16 most recent publications (2024–2025), a clear pattern emerges of translational epidemiology : moving from descriptive risk-factor associations to actionable clinical and economic evaluations. Studies repeatedly integrate multi-source Swedish registry data (4.1 million individuals) with genomic and health-economic modelling to inform precision oncology. Supervision & grants Häggström has served as Assistant supervisor on the doctoral dissertation project “Pinpointing the Association between Obesity and Cancer Risk” (2020–2024), led by PhD candidate Sun M, with main supervisor Dr. Tanja Stocks and additional assistant supervisor Dr. Josef Fritz. The project has achieved widespread dissemination, being covered by 24 news outlets and attracting 39 Mendeley readers. Laboratory / Research group While no formal laboratory name is provided, her affiliation with Lund University’s register-based epidemiology environment and her extensive collaboration network across Sweden and Europe indicate participation in a multi-disciplinary team leveraging national quality-of-care and population registries.

• Radiology
• Nuclear Medicine
• Medical Imaging
• +۴ مورد دیگر

Assoc. Prof. Elif Gündoğdu is an Associate Professor at Eskisehir Osmangazi University Faculty of Medicine, Department of Internal Medicine Sciences, Radiology Division. She has been serving in this position since 2020, previously holding the rank of Assistant Professor from 2017-2020 at the same institution. Her clinical expertise spans abdominal imaging, genitourinary radiology, and transplant imaging, with particular focus on CT and MRI applications in diagnosing complex conditions. Dr. Gündoğdu completed her undergraduate medical education at Ankara University Faculty of Medicine between 2001-2007. She then pursued specialized training in radiology through expert-level medical education at Ankara Training and Research Hospital from 2007-2011. Her professional journey includes clinical radiology positions at the Ministry of Health from 2012-2017, where she served as a Radiology Specialist Doctor. Her research interests encompass Radiology, Nuclear Medicine, Medical Imaging, Transplantation, and Internal Medicine Sciences, with numerous publications focusing on abdominal imaging, genitourinary system radiology, and advanced CT/MRI techniques. She has made significant contributions to the understanding of adrenal imaging, renal pathologies, pancreatic disorders, and infectious processes visible through radiological methods. Her work often bridges clinical medicine with advanced imaging techniques to improve diagnostic accuracy and patient outcomes. Dr. Gündoğdu has supervised multiple theses across various medical imaging topics, including renal cell carcinoma differentiation, abdominal fat tissue analysis, and multiparametric MRI applications in urological cancers. Her scholarly activity includes serving as a peer reviewer for numerous prestigious journals including Academic Radiology, British Journal of Radiology, and Turkish Journal of Medical Sciences since 2020. She actively participates in national radiology congresses as both a session moderator and invited speaker, particularly at the Turkish Radiology Congress (TÜRKRAD). Her academic leadership extends to teaching undergraduate courses such as Urogenital System Radiological Algorithm and Medical Imaging I at the associate degree level. Dr. Gündoğdu has also contributed book chapters on adrenal gland pathologies, contrast agent usage in geriatrics, and urinary system radiology, demonstrating her commitment to advancing medical knowledge and education in her field.

Carina Bernardoمشاهده پروفایل

پژوهشگر

• Bladder Cancer
• Genomics
• Molecular Pathology
• +۵ مورد دیگر

Carina Bernardo is an active Associate Researcher and Urothelial Cancer Genomics Researcher at Lund University Cancer Centre (LUCC), Lund University. Her primary affiliation is with the Department of Urology (implied by email domain med.lu.se and research focus), where she serves as Principal Investigator for tumor heterogeneity projects and Assistant Supervisor for doctoral research. Her research expertise centers on bladder cancer molecular subtyping, with a fingerprint showing 100% Patient Medicine/Dentistry and 96% Bladder Cancer focus. Key areas include cancer taxonomy development (LundTax algorithm), metastasis patterns across molecular subtypes, tumor microenvironment interactions, and organoid-based drug response modeling. Recent work demonstrates limited plasticity of bladder cancer subtypes in metastatic settings and clinical utility of molecular classification for cisplatin-treated patients. Analysis of her 15 most recent publications reveals consistent focus on translational oncology, with 60% directly addressing bladder cancer molecular classification systems. Her work bridges genomics, computational biology, and clinical oncology, increasingly incorporating organoid technology and immunotherapy approaches since 2022. The 2023 Science Immunology paper on dendritic cell reprogramming (39 citations) marks expansion into tumor immunogenicity. Principal Investigator: Dissecting tumor heterogeneity with organoid models (Mrs. Berta Kamprad's Cancer Foundation, 2024-2027) Assistant Supervisor: Functional variants in breast cancer splicing (2023-present) She actively organizes LUCC symposia on advanced tumor models and imaging, with recent speaking engagements at the 2025 UroCAN Retreat and 2023 Immunology Minisymposium. Her collaborative network spans 12 international institutions focusing on bladder cancer genomics and precision oncology.

• Urologic Oncology
• Artificial Intelligence in Medicine
• Health Disparities in Cancer Care
• +۵ مورد دیگر

Bogdana Schmidt, MD, MPH, is a clinical Clinical Assistant Professor in the Department of Surgery at the University of Utah . She practices at the Huntsman Cancer Institute and Veterans Administration Medical Center , specializing in urologic oncology with expertise in bladder, kidney, prostate, testis, and penile cancer . Education: MD from University of California, San Francisco School of Medicine; MPH from University of California, Los Angeles; Residency and Fellowship in urologic oncology at UCSF and Stanford University. Her research focuses on integrating artificial intelligence and advanced imaging into urologic care, optimizing surgical outcomes, and addressing health disparities in cancer treatment. Recent publications highlight applications of AI in Gleason grading, obesity's impact on prostate cancer survival, and novel staging systems like STAR-CAP. Patients praise her professionalism, communication skills, and compassionate care , with a 4.9/5 rating based on 348 reviews. She has contributed to studies on minimally invasive procedures , cost analysis , and ethical reforms in clinical practice.